BridgeBio Oncology Therapeutics Inc [BBOT] stock is trading at $12.2, up 2.26%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The BBOT shares have gain 6.74% over the last week, with a monthly amount drifted -0.73%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
BridgeBio Oncology Therapeutics Inc [NASDAQ: BBOT] stock has seen the most recent analyst activity on December 05, 2025, when Morgan Stanley initiated its Overweight rating and assigned the stock a price target of $20. Previously, Leerink Partners started tracking the stock with Outperform rating on September 17, 2025, and set its price target to $25. On September 15, 2025, H.C. Wainwright initiated with a Buy rating and assigned a price target of $27 on the stock. Piper Sandler started tracking the stock assigning an Overweight rating and suggested a price target of $21 on August 15, 2025.
BridgeBio Oncology Therapeutics Inc [BBOT] stock has fluctuated between $8.50 and $14.87 over the past year. Currently, Wall Street analysts expect the stock to reach $23.2 within the next 12 months. BridgeBio Oncology Therapeutics Inc [NASDAQ: BBOT] shares were valued at $12.2 at the most recent close of the market. An investor can expect a potential return of 90.16% based on the average BBOT price forecast.
Analyzing the BBOT fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.24, Equity is -0.77 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 11.92 points at the first support level, and at 11.64 for the second support level. However, for the 1st resistance point, the stock is sitting at 12.41, and for the 2nd resistance point, it is at 12.63.
Ratios To Look Out For
For context, BridgeBio Oncology Therapeutics Inc’s Current Ratio is 13.33. Further, the Quick Ratio stands at 13.33, while the Cash Ratio is 11.45.
